MDMercedes Delgado-Valverde

Mercedes Delgado-Valverde

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mercedes Delgado-Valverde has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Erratum for Recacha et al., “Characterization of a bla KPC-3 -carrying plasmid in a clinical isolate of Klebsiella pneumoniae belonging to the emerging successful clone ST147”

    by Esther Recacha, Mercedes Delgado-Valverde, Marina R. Pulido, Elena Pérez-Nadales, Patricia Pérez-Palacios, Inés Portillo-Calderón, Juan Manuel Sánchez-Calvo, Irene Gracia-Ahufinger, Álvaro Pascual

  • Mechanisms of resistance to newer drugs against gram negative bacteria in enterobacterales

    by Mercedes Delgado-Valverde, Patricia Perez-Palacios, Lorena López-Cerero


  • Open Access

    Characterization of a bla KPC-3 -carrying plasmid in a clinical isolate of Klebsiella pneumoniae belonging to the emerging successful clone ST147

    by Esther Recacha, Mercedes Delgado-Valverde, Marina R. Pulido, Elena Pérez-Nadales, Patricia Pérez-Palacios, Inés Portillo-Calderón, Juan Manuel Sánchez-Calvo, Irene Gracia-Ahufinger, Álvaro Pascual

    Klebsiella pneumoniae ST147 has emerged as a successful clone able to efficiently disseminate a number of carbapenemases, including bla KPC . This study compared a representative bla KPC-3 -carrying plasmid of an ST147 clone with plasmids that usually harbor bla KPC-3 belonging to the high-risk clone ST512. Five clinical isolates of KPC-3-producing K. pneumoniae belonging to ST147 isolated in Southern Spain were analyzed. The first ST147 isolate detected was compared with two previous isolates of K. pneumoniae ST512/KPC-3 and KPC-3-encoding plasmid pKpQIL as reference plasmid. Microdilution, disk diffusion, β-CARBA test, and NG-Test CARBA 5 were used for antimicrobial susceptibility analysis and phenotypic characterization of the isolates according to EUCAST guidelines. Molecular characterization was performed using pulsed-field gel electrophoresis (PFGE)- Xba I, sequenced (by Illumina and Oxford Nanopore) and annotated with open-source databases (CGE tools and RAST). Plasmid incompatibility groups were analyzed using PlasmidFinder; BRIG was used to compare the bla KPC-3 -harboring plasmids from three of the selected clinical isolates with each other and with pKpQIL. Clinical isolates of ST147/KPC-3 showed resistance to β-lactams, fluoroquinolones, and aminoglycosides. Clinical isolates ST147/KPC-3 and ST512/KPC-3 had identical PFGE patterns in each clone. Plasmid replicon analysis showed a plasmid with the formula IncFII (K2:A-:B-) in the ST512 isolates, identical to pKpQIL; the ST147 isolates harbored IncFII (K1:A-:B-), although the genetic environment of bla KPC-3 was the same as pKpQIL, which is Tn 4401 _IS Kpn7 upstream of bla KPC-3 and IS Kpn6 downstream of bla KPC-3 . Plasmids harboring bla KPC-3 in ST147 and ST512 are different, although differences are subtle. The genetic environment of bla KPC-3 in the different sequence types is very conservative and identical to pKpQIL. IMPORTANCE: The successful spread of bla KPC is primarily due to the dissemination of K. pneumoniae isolates belonging to high-risk clonal complex 258 (ST258, ST11, and ST512); however, new clones are emerging globally as the ST147 clone. In this study, we compare the genetic environment of a representative bla KPC-3 -carrying plasmid of an ST147 clone with plasmids that usually harbor bla KPC-3 belonging to the high-risk clone ST512. Plasmids harboring bla KPC-3 detected in ST512 and ST147 were different; however, the close genetic environments of bla KPC-3 in the different plasmids (ST147 and ST512) remained conserved.


  • Open Access

    Reporting antimicrobial susceptibility and detection of carbapenemase production in single and double carbapenemase-producing Gram-negative clinical isolates: a nationwide proficiency study

    by Felipe Fernández-Cuenca, Mercedes Delgado-Valverde, Pablo Guridi-Fernández, Concepción Gimeno-Cardona, Carmen Hidalgo-Díaz, Álvaro Pascual

    Purpose: The objective was to assess the ability of Spanish clinical microbiology laboratories to report reliable carbapenem susceptibility test results and to detect carbapenemase production (CP) and/or carbapenemase genes in double (DCP) and single carbapenemase-producing (SCP) isolates.Methods: Twelve isolates (8 SCP and 4 DCP) selected from the Andalusian Reference Laboratory were sent to 83 laboratories with requests for MICs and phenotypic and genotypic tests used for CP.Results: Overall, there was lower essential agreement and a higher number of clinical errors in DCP than in SCP isolates. Phenotypic tests showed higher sensitivity for DCP isolates than for SCP isolates: lateral flow immunoassay (99.0% vs. 95.1%), carbapenem inactivation method (100% vs. 93%) and chromogenic media (100% vs. 83.3%); conversely, sensitivities for DCP versus SCP isolates was lower using disk diffusion with inhibitors (83.3% vs. 90.4%) and hydrolysis-based assays (81.3% vs. 86.1%). Molecular methods showed higher sensitivity for DCP isolates than phenotypic methods, and higher sensitivity for DCP isolates than for SCP isolates. In addition, concordance between genes detected and the reference was higher in DCP than in SCP isolates (98.9% vs. 83%). However, blaVIM-1 and blaIMP-8 were not detected in 77.5% and 42.2% of the determinations, respectively, for DCP isolates.Conclusion: The main differences between DCP versus SCP isolates were the lower reliability of gradient strips, higher overall sensitivity of phenotypic methods for DCP isolates, but lower sensitivity with disk diffusion inhibitors and hydrolysis-based assays. Molecular assays were generally more sensitive for carbapenemase gene detection in DCP than in SCP isolates, although concordance was lower.


  • Open Access

    Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

    by Mercedes Delgado-Valverde, Inés Portillo-Calderón, Manuel Alcalde-Rico, M. Carmen Conejo, Carmen Hidalgo, Carlos del Toro Esperón, Álvaro Pascual

    Purpose: Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-susceptible P. aeruginosa and K. pneumoniae ST258 and ST512 KPC producers belonging to different lineages from hospitals in Southern Spain. Methods: Six hundred and seventy-eight isolates were tested: 265 K. pneumoniae (230 ST512/KPC-3 and 35 ST258/KPC-3) and 413 carbapenem-non-susceptible P. aeruginosa. Imipenem, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, ceftolozane/tazobactam, meropenem, amikacin, ciprofloxacin, colistin, and ceftazidime/avibactam were used as comparators against P. aeruginosa. Against K. pneumoniae ceftazidime, cefepime, aztreonam, and ceftolozane/tazobactam were not tested, and tigecycline was studied instead. MICs were determined in duplicate by broth microdilution according to EUCAST guidelines. Results: Imipenem/relebactam displayed potent in vitro activity against both sequence types of KPC-3-producing K. pneumoniae. MIC50 and MIC90 values were 0.25 mg/L and 1 mg/L, respectively, with percent of susceptible isolates >97%. Only three K. pneumoniae ST512/KPC-3 isolates and one ST258/KPC-3 were resistant to imipenem/relebactam. Relebactam sensitized 98.5% of K. pneumoniae isolates resistant to imipenem. The activity of imipenem/relebactam against P. aeruginosa was moderate (susceptibility rate: 62.7%). Analysis of the acquired and mutational resistome of isolates with high levels of resistance to imipenem/relebactam has not shown a clear association between them. Conclusion: Imipenem/relebactam showed excellent activity against K. pneumoniae KPC-3. The activity of imipenem/relebactam against imipenem-resistant P. aeruginosa was moderate.


  • Open Access

    In Vitro Activity of Cefiderocol Compared to Other Antimicrobials against a Collection of Metallo-Beta-Lactamase-Producing Gram-Negative Bacilli from Southern Spain

    by M. Delgado-Valverde, I. Portillo-Calderón, E. Recacha, P. Pérez-Palacios, A. Pascual

    This article demonstrates the efficacy of cefiderocol against a large collection of well-characterized metallo-beta-lactamase-producing isolates, some of them even producing double carbapenemases. Furthermore, cefiderocol activity is compared to other novel broad-spectrum antimicrobials with activity against carbapenemases.


  • In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

    by Marta Hernández-García, María García-Castillo, José Melo-Cristino, Margarida F Pinto, Elsa Gonçalves, Valquíria Alves, Ana Raquel Vieira, Elmano Ramalheira, Luísa Sancho, José Diogo, et al.

    To study the in vitro activity of imipenem/relebactam and comparators and the imipenem/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017–18) and Spain (SUPERIOR, 2016–17) surveillance studies. P. aeruginosa isolates (n = 474) were prospectively recovered from complicated urinary tract (cUTI), complicated intra-abdominal (cIAI) and lower respiratory tract (LRTI) infections in 11 Portuguese and 8 Spanish ICUs. MICs were determined (ISO broth microdilution). All imipenem/relebactam-resistant P. aeruginosa isolates (n = 30) and a subset of imipenem/relebactam-susceptible strains (n = 32) were characterized by WGS. Imipenem/relebactam (93.7% susceptible), ceftazidime/avibactam (93.5% susceptible) and ceftolozane/tazobactam (93.2% susceptible) displayed comparable activity. The imipenem/relebactam resistance rate was 6.3% (Portugal 5.8%; Spain 8.9%). Relebactam restored imipenem susceptibility to 76.9% (103/134) of imipenem-resistant isolates, including MDR (82.1%; 32/39), XDR (68.8%; 53/77) and difficult-to-treat (DTR) isolates (67.2%; 45/67). Among sequenced strains, differences in population structure were detected depending on the country: clonal complex (CC)175 and CC309 in Spain and CC235, CC244, CC348 and CC253 in Portugal. Different carbapenemase gene distributions were also found: VIM-20 (n = 3), VIM-1 (n = 2), VIM-2 (n = 1) and VIM-36 (n = 1) in Spain and GES-13 (n = 13), VIM-2 (n = 3) and KPC-3 (n = 2) in Portugal. GES-13-CC235 (n = 13) and VIM type-CC175 (n = 5) associations were predominant in Portugal and Spain, respectively. Imipenem/relebactam showed activity against KPC-3 strains (2/2), but was inactive against all GES-13 producers and most of the VIM producers (8/10). Mutations in genes affecting porin inactivation, efflux pump overexpression and LPS modification might also be involved in imipenem/relebactam resistance. Microbiological results reinforce imipenem/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR/XDR P. aeruginosa isolates, except for GES-13 and VIM producers.


  • Molecular characterisation of an outbreak of NDM-7-producing Klebsiella pneumoniae reveals ST11 clone expansion combined with interclonal plasmid dissemination

    by Jesús Machuca, Lorena Lopez-Cerero, Manuel Rodríguez-Maresca, Felipe Fernández-Cuenca, Inmaculada López-Hernández, Mercedes Delgado-Valverde, Waldo Sanchez-Yebra, Álvaro Pascual


  • Transfer of plasmids harbouring blaOXA-48-like carbapenemase genes in biofilm-growing Klebsiella pneumoniae: Effect of biocide exposure

    by Patricia Perez-Palacios, Ana Gual-De-Torrella, Mercedes Delgado-Valverde, Jesús Oteo-Iglesias, Carmen Hidalgo-Díaz, Álvaro Pascual, Felipe Fernández-Cuenca


  • Open Access

    Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae

    by Vicente Merino-Bohórquez, Fernando Docobo-Pérez, Adoración Valiente-Méndez, Mercedes Delgado-Valverde, Manuel Cameán, William W. Hope, Álvaro Pascual, Jesús Rodríguez-Baño

    This study analyzes the pharmacokinetic variability of piperacillin in non-critically ill patients with Enterobacteriaceae bloodstream infections (EBSI) and explores predicted clinical outcomes and piperacillin-related neurotoxicity under different renal conditions. Hospitalized, non-critically ill patients treated with piperacillin–tazobactam for EBSI were included. Four serum samples per patient were collected and analyzed. A population pharmacokinetic model was developed using the Pmetrics package for R. Monte Carlo simulations of various dosage regimens of 4 g piperacillin, administered q8 h or q12 h by short (0.5 h) or long (4 h) infusion, following the different glomerular filtration rate (GFR) categories used to classify chronic kidney disease (Kidney Disease: Improving Global Outcomes, KDIGO) to determine the probability of target attainment (PTA) using a free drug concentrations above the minimal inhibitory concentration (fT > MIC) of 50% for efficacy and targets for piperacillin-associated neurotoxicity. Twenty-seven patients (102 samples) were included. Extended piperacillin infusions reached a PTA > 90% (50%fT > MIC) within the susceptibility range, although a loading dose did not greatly improve the expected outcome. Long infusions reduced the expected toxicity in patients with severe renal impairment. The study supports the use of extended infusions of piperacillin in non-critically ill patients with EBSI. No benefits of a loading dose were expected in our population. Finally, extended infusions may reduce the risk of toxicity in patients with severe renal impairment.